AKT1 and colorectal carcinoma: Using MK2206, we confirmed the mechanistic effect of MDFI on CRC, and MK2206 is an AKT-specific inhibitor.17 Compared with that of HCT116 and SW620 cells without the treatment of MK2206, the survival rate of CRC cells decreased significantly after treatment with MK2206 for 24 h (Figure 6a–b).